Bladder-Bowel Dysfunction (BBD)
محل انتشار: سی و هفتمین کنگره بیماری های کودکان
سال انتشار: 1404
نوع سند: مقاله کنفرانسی
زبان: انگلیسی
مشاهده: 22
متن کامل این مقاله منتشر نشده است و فقط به صورت چکیده یا چکیده مبسوط در پایگاه موجود می باشد.
توضیح: معمولا کلیه مقالاتی که کمتر از ۵ صفحه باشند در پایگاه سیویلیکا اصل مقاله (فول تکست) محسوب نمی شوند و فقط کاربران عضو بدون کسر اعتبار می توانند فایل آنها را دریافت نمایند.
- صدور گواهی نمایه سازی
- من نویسنده این مقاله هستم
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
PEDIATRICS37_380
تاریخ نمایه سازی: 14 شهریور 1405
چکیده مقاله:
Bladder-Bowel Dysfunction (BBD) is a common and often under-recognized condition in pediatric patients, characterized by coexisting lower urinary tract symptoms (LUTS) and bowel irregularities, particularly functional constipation. Retained stool in the rectum may mechanically or neurologically influence bladder function, leading to urgency, incontinence, and post-void residual. This syndrome not only compromises the child's quality of life but is also associated with recurrent urinary tract infections (UTIs), vesicoureteral reflux, and potential long-term renal damage. Early identification of BBD is essential. Diagnosis involves a combination of detailed history, physical examination, and diagnostic tools including bladder diaries, uroflowmetry, post-void residual (PVR) measurement by ultrasound, and in complex cases, urodynamic studies. Abdominal ultrasound is also helpful in assessing stool burden, bladder wall thickness, and upper urinary tract abnormalities. In complex cases, urodynamic studies provide valuable insight. Recent years have significant advances in the understanding, diagnosis, and management of BBD. Management of BBD is multidisciplinary and stepwise. Management begins with behavioral therapy, bowel regulation (often using polyethylene glycol or stimulant laxatives), followed by pharmacological intervention for bladder symptoms using anticholinergics, beta-۳ agonists, or alpha-blockers. Pharmacological management of bladder symptoms may include anticholinergic agents (e.g., oxybutynin, tolterodine) to reduce detrusor overactivity, beta-۳ adrenergic agonists (e.g., mirabegron), and alpha-blockers for suspected bladder outlet obstruction. In refractory cases, more advanced treatments such as neuromodulation (e.g., posterior tibial nerve stimulation) or intravesical botulinum toxin injections may be considered. In children with neurogenic bladder or spinal dysraphism, multidisciplinary care involving nephrology, urology, gastroenterology, and rehabilitation specialists is crucial.
نویسندگان
Zahra Nouparast
Department of pediatric Nephrology, Bahrami Children hospital, school of medicine, Tehran university of Medical Science, Tehran, Iran
Sayed Yousef Mojtahedi
Department of pediatric Nephrology, Bahrami Children hospital, school of medicine, Tehran university of Medical Science, Tehran, Iran